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Abstract
Aim: To evaluate the outcome of adjustable continence balloons in the treatment of
stress urinary incontinence (SUI) after transurethral resection of the prostate (TURP).
Methods: In two tertiary centers, adjustable continence balloons were
implanted in 29 patients with post‐TURP SUI between 2007 and 2018.
Endpoints of this retrospective multicenter study were patient‐reported changes
in pad count and complications. Dry was defined as no pad or one security pad.
Results: Preoperative urinary incontinence was mild in 7 (24%), moderate in 12
(41%), and severe in 10 (35%) patients. The median follow‐up duration was 21
(interquartile range [IQR], 11‐43) months. Within 30 days postoperatively, a
Clavien‐Dindo grade less than or equal to II complication occurred in 24% of the
patients. Reintervention rate was 24%. Six and 12 months after implantation, the
International Prostate Symptom Score (IPSS) quality‐of‐life item improved
significantly from 5 (IQR, 5‐6) preoperatively to 3 (IQR, 1‐4.5) and 1 (IQR, 0‐3),
respectively. At last visit (median 21 months after implantation), the outcome on
continence had improved in 76% of the patients, including, 45% dry patients. After
a median follow‐up of 28 months (IQR, 13‐63; N= 23), all but one patient reported
improvement on the Patient Global Impression of Improvement (PGI‐I) scale. In
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detail, 10 patients reported “very much better” condition compared with before the
implantation, 10 patients “much better,” two patients “a little better,” and one
patient “no change.” Daily pad use decreased from three (IQR, 2‐5) to one (IQR,
0‐2) pads/day (P<0.001).
Conclusions: This is hitherto, the first study reporting results of adjustable
continence balloons in the treatment of post‐TURP SUI. The therapy was found
to be safe and efficient. The majority of our study population reported
improvement on their condition and greater than or equal to 50% reduction in
daily pad use.
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1 | INTRODUCTION
A transurethral resection of the prostate (TURP) is
currently the standard surgical procedure in the treat-
ment of a bladder outlet obstruction caused by benign
prostate enlargement.1,2 A rare but unfortunate compli-
cation is post‐TURP urinary incontinence.3 Post‐TURP
urinary incontinence can be due to damage to the
sphincter, pre‐existing bladder dysfunction, or new onset
bladder dysfunction.3 According to the International
Consultation on Incontinence (ICI), the incidence of
post‐TURP stress urinary incontinence (SUI) is about 1%,
irrespective of the TURP techniques used (ie, monopolar,
bipolar, or laser).3
Urinary incontinence after prostate surgery can signifi-
cantly alter a person's quality of life.4,5 In cases of male SUI
secondary to sphincter deficiency, conservative treatment
may be tried for periods up to 6 to 12 months in advance of
a surgical treatment.3-5 When conservative treatment fails,
several surgical implants are available, such as the artificial
urinary sphincter, male sling, and adjustable continence
balloons.3-5 The latter device consists of two periurethrally
placed balloons (ProACTTM) whose volumes can be
adjusted to achieve the optimal balance between voiding
pressure and continence.6 Reported long‐term dry rates (no
pad or one security pad) range from 45% to 66% with a
follow up of 56 to 58 months.7-9 The majority or all patients
included in these studies were treated for SUI after radical
prostatectomy. Patients with post‐TURP SUI are a different
population in view of a different mechanism of injury.
Usually, it is damage to the proximal part of the external
striated urethral sphincter distal to the verumontanum.4
The aim of this retrospective multicenter study was to
evaluate the efficacy of adjusted continence balloons in
patients with post‐TURP SUI. Efficacy and safety were
evaluated in terms of achieving continence, changes in
pads use, complications, re‐interventions and patient‐
reported estimates of improvement assessed with the
Patient Global Impression of Improvement (PGI‐I) scale.
2 | PATIENTS AND METHODS
We retrospectively evaluated data prospectively collected
from all patients who had the ProACTTM (Uromedica
Inc, Plymouth, MN) device implanted as surgical treat-
ment of post‐TURP SUI after May 2007 in two tertiary
centers: Erasmus University Medical Center in Rotter-
dam, the Netherlands and Policlinico Tor Vergata in
Rome, Italy. Conservative treatment with pelvic floor
exercises had failed in all patients. Urethrocystoscopy
and urodynamic study were performed to rule out
urethral strictures and to evaluate the bladder function.
Exclusion criteria were a history of radiotherapy,
neurogenic bladder dysfunction, and a male sling or an
artificial urinary sphincter (AUS) in situ. The local ethics
committee of Erasmus University Medical Center in
Rotterdam approved this study (MEC‐2017‐05 and MEC‐
2018‐1287). The Comitato Etico Policlinico Tor Vergata
in Rome gave a general permission to anonymously
collect data for scientific purposes.
Preoperative assessment included medical history,
anamnestic daily pad count, voiding diary, and Interna-
tional Prostate Symptom Score (IPSS). The preoperative
severity of urinary incontinence was determined by the
anamnestic daily pad count, classified as mild (1‐2 pads),
moderate (3‐4 pads), or severe (≥5 pads). In each
institution, one experienced surgeon had implanted the
adjustable continence balloons using the technique
described by Hübner and Schlarp.6 In brief, two
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ProACTTM balloons were implanted via two incisions in
the perineum, at either side of the bladder neck. Most of
the patients were under general anesthesia and some
under spinal anesthesia during the procedure. Intrave-
nous cefazolin and metronidazole were given periopera-
tively as antibiotic prophylaxis. After removal of the
transurethral catheter and a successful voiding trial,
patients were discharged from the hospital on the day of
surgery or the day after. Within a period of 6 months after
the implantation, the balloon volume was adjusted at the
outpatient clinic by needle puncture of the subcutaneous
port in the scrotum. Postoperative assessment included
anamnestic daily pad count, IPSS, and complications.
All patients in Rotterdam received an information
letter, a three‐item questionnaire and a return envelope
by post. In Rome, those three questions were asked
during the last scheduled outpatient visit. The three
questions asked were:
1. “Would you recommend adjustable continence bal-
loons to someone else?” to be answered by yes or no.
2. Which number describes how your condition is now
compared to before the adjustable continence bal-
loons: (1) “very much better,” (2) “much better,” (3)
“a little better,” (4) “no change,” (5) “a little worse,”
(6) “much worse,” (7) “very much worse” (PGI‐I
scale).
3. How many pads do you use daily?
Other relevant patient characteristics were retrospec-
tively retrieved from the medical charts. Treatment
outcome on continence was assessed by the change in
preoperative and postoperative anamnestic daily pad use.
The definition of “dry” was no pad or a single security
pad /day. “Improvement” was defined as a daily pad
reduction of greater than or equal to 50% compared with
the preoperative situation. “Little/no improvement” was
defined as no or less than 50% reduction of daily pad use
compared with preoperative. Perception of improvement
on condition was assessed with the PGI‐I (7‐points) scale;
a lower score corresponds with a better condition.
Complications within 30 days were classified by the
Clavien‐Dindo Classification of Surgical Complications.10
Failure of the interventions was defined as explantation
with or without revision of adjustable continence
balloons, or as an additional surgical procedure because
of persistent incontinence, or as acceptance of the
situation with persistent incontinence.
Statistical analyses were performed using SPSS version
24.0 (IBM Corp, Armonk, NY). Descriptive statistics are
presented as percentages for qualitative variables and
median and interquartile range (IQR) for quantitative
variables. The Wilcoxon signed‐rank test was used to
compare preoperative and postoperative quantitative
variables. Pearson's χ2 test was used to compare
categories. Time to adjustable continence balloons failure
is distributed in a Kaplan‐Meier curve. A two‐sided
P< 0.05 was considered statistically significant.
3 | RESULTS
Twenty‐nine of 31 eligible patients were included; 26
patients in Rotterdam and five in Rome. Reason for
exclusion in two patients was a nonfunctional male sling
in situ, both patients were included in Rotterdam.
Urinary incontinence was classified as mild in 7
(24.1%), moderate in 12 (41.4%), and severe in 10
(34.5%) patients. Median preoperative anamnestic pad
use per day was 3.5 (IQR, 2.3‐5.3). The median time
between TURP and balloon implantation was 2.2 (IQR,
1.3‐3.6) years. TURP had been performed because of
lower urinary tract symptoms secondary to benign
prostate enlargement. Two patients had prior anti‐
incontinence surgery with bulking agents. Preoperative
assessment of the external urethral sphincter with
urethrocystoscopy showed normal findings in 15
(51.7%) patients; three out of 15 patients had severe
incontinence. The sphincter remained open in 14 (48.3%)
patients; severe incontinence was seen in seven of 14
patients. More severe incontinence was seen in patients
with abnormal urethrocystoscopy findings (50.0% vs
20.0%; P= 0.09). Patient characteristics are shown in
Table 1.
3.1 | Continence outcome
The median number of balloon volume adjustments after
implantation was five (Table 1). Six months after
implantation, the median pad use per day was 1.0
(IQR, 1.0‐1.9); after 1 year it was 1.0 (IQR, 0.0‐2.5). The
IPSS quality of life score had improved significantly from
preoperative 5.0 (IQR, 5.0‐6.0) to 3.0 (IQR, 1.0‐4.5)
6 months after implantation and to 1.0 (IQR, 0.0‐3.0)
1 year after implantation. The median time between
implantation and the last outpatient visit was 20.9 (IQR,
10.5‐43.4) months. The daily pad use reported at the last
visit was 1.0 (IQR, 0.0‐2.0). At the last visit, 75.8% (22 of
29) of the patients reported greater than or equal to 50%
reduction in daily pad use against the preoperative,
including, 44.8% (13 of 29) who had become dry. The
seven patients with preoperative mild incontinence were
all dry at last visit. In the 12 patients with preoperative
moderate incontinence, the outcome at last visit was: dry
in four, improved in three, and little or no improvement
in five patients. Two of ten patients with preoperative
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severe incontinence were dry, six patients were
improved, and two patients had little or no improvement.
In the whole study population, one patient needed a
single readjustment of the balloons (0.5 mL) more than
5 years after the last adjustment. The other patients had
no additional adjustments. Table 2 provides details on
daily pad use, the postoperative outcome on continence,
and IPSS.
3.2 | Questionnaire
After a median follow‐up of 28.1 (IQR, 12.8‐62.9) months,
23 patients had completed the three‐item questionnaire
(response rate 79.0%). Two patients did not respond and
four patients (minimal 4 months after the end of follow‐up)
had died at the time the questionnaire was sent. The reason
for death was not related to the surgical procedure. Results
are presented in Table 3. All patients would recommend
adjustable continence balloons to someone else. Daily pad
use improved significantly from 3.0 (IQR, 2.0‐5.0) to 1.0
(IQR, 0.0‐2.0) pads/day (P< 0.001). The outcome on
continence had improved in 15 (65.2%) of the patients,
including six (26.1%) dry patients. Twenty‐two (95.7%)
patients reported improvement on the PGI‐I scale. In detail,
the condition now compared with the condition before the
adjustable continence balloons was reported “very much
better” in 10 (43.5%) patients, “much better” in 10 (43.5%)
patients, “a little better” in two (8.7%) patients, and “no
change” in one (4.3%) patient.
3.3 | Complications
In one patient an intraoperative complication occurred,
that is, a perforation of the urethra during positioning of
the right balloon. The balloon was still placed just lateral
to the perforation. In contrast to the other patients, this
TABLE 1 Patient and clinical characteristics presented as
number (%) or median (interquartile range)
Characteristics (n = 29)a
Age, y 70.5 (66.7‐77.7)
Weight, kg 82.0 (75.5‐94.0)
BMI, kg/m2 27.5 (24.8‐30.0)
Type of TURP
Monopolar or bipolar 24 (82.8)
Laser 5 (17.2)
ASA score
I 3 (10.3)
II 18 (62.1)
III 8 (27.6)
Type of anesthesia
General 20 (69.0)
Spinal 9 (31.0)
Operating time, minutes (n = 28) 33.0 (26.8‐38.5)
Number of adjustments 5.0 (2.0‐5.5)
Volume left balloon, mL 5.0 (2.0‐6.5)
Volume right balloon, mL 5.0 (2.0‐6.5)
Complications within 30 days
No complication 22 (75.9)
Clavien‐Dindo grade I 6 (20.7)
Clavien‐Dindo grade II 1 (3.4)
aUnless stated otherwise.
TABLE 2 The outcome on daily pad usage, continence, IPSS total, and IPSS QoL, presented as number (%) or median (IQR)
Preoperative
6 mo after
implantation
1 y after
implantation
Last visit median FU
20.9 (10.5‐43.4) mo
Anamnestic pads/d n = 29 n = 28 n = 21 n = 29
Median (IQR) 3.5 (2.3‐5.3) 1.0 (1.0‐1.9) 1.0 (0.0‐2.5) 1.0 (0.0‐2.0)
P (difference from preoperative)a – < 0.001 0.004 < 0.001
Postoperative outcome on continence n = 28 n = 21 n = 29
Dry, n (%) – 9 (32.1) 6 (28.6) 13 (44.8)
≥50%‐99% reduction in daily pad
use, n (%)
– 12 (42.9) 7 (33.3) 9 (31.0)
Little or no improvement, n (%) – 7 (25.0) 8 (38.1) 7 (24.1)
IPSS total n = 20 n = 25 n = 15
Median (IQR) 13.0 (10.3‐16.0) 7.0 (4.0‐14.5) 6.0 (3.0‐10.0) –
P (difference from preoperative)a – 0.001 0.007
IPSS QoL n= 20 n = 25 n = 15
Median (IQR) 5.0 (5.0‐6.0) 3.0 (1.0‐4.5) 1 (0.0‐3.0) –
P (difference from preoperative)a – 0.001 0.005 –
Abbreviations: FU, follow‐up; IPSS, International Prostate Symptom Score; IQR, interquartile range; QoL, quality of life.
aThe Wilcoxon signed‐rank test was used to compare preoperative and postoperative results.
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patient was discharged from the hospital with a
transurethral catheter. Five days postoperatively, prophy-
lactic antibiotics were started and the transurethral
catheter was removed. At 6 and 12 months postoperative,
his pad use was improved from 6 pads/day preoperative
to 2.5 and 1.5 pads/day, respectively.
Twenty‐two (75.9%) patients were complication‐free
within 30 days postoperatively. The remaining seven
patients had acute urinary retention. The balloon volume
was reduced in one patient, which resulted in a
successful voiding trial. In the other six patients, the
transurethral catheter was replaced and removed at day 5
or 7 with oral antibiotics started at approximately the
removal time. In one of these patients, epididymitis was
treated with oral antibiotics 3 days after removal of the
transurethral catheter.
Failure of the intervention was seen in nine (31.0%)
patients after a median follow‐up of 18.1 (IQR, 8.4‐21.6)
months. The failure‐free survival curve is presented in
Figure 1. Four patients had unchanged urinary incon-
tinence of whom two accepted the situation. The other
two patients had additional surgery with bulking agents.
At last visit, the outcome on continence was improved in
both patients. One or more replacements were performed
in five patients; in two on account of malposition of the
balloon and in three on account of a defective of the
balloon. A second replacement was necessary in two
patients because of erosion of one of the balloons through
the urethra. The outcome on continence at last visit was
in three patients little or no improvement, and in two
patients improvement, including one dry patient.
Preoperative severe incontinence was seen in six
(66.7%) of the nine patients in whom the intervention
had failed vs four (20.0%) of the 20 patients in whom the
intervention was successful (P= 0.014).
4 | DISCUSSION
The aim of this study was to evaluate the efficacy of
adjustable continence balloons in the treatment of post‐
TURP SUI. After a median follow‐up of 21 months, two‐
thirds (22 of 29) of the patients reported to use fewer pads
daily, and 13 of the 29 patients were even dry. All but one
patient reported improvement on the PGI‐I scale. Within
30 days postoperatively, a Clavien‐Dindo grade less than
or equal to II complication had occurred in 24% of the
patients.
Male postsurgical SUI can be caused by direct surgical
injury to the external urethral sphincter or its innerva-
tion, though this may coexist with bladder dysfunction.4,5
Post‐TURP SUI is most likely the result of damage to the
proximal part of the external urethral sphincter distal to
the verumontanum.4 Several additional mechanisms of
sphincteric injury after radical prostatectomy have been
suggested, like: ischemia and immobilization by scar,
atrophy due to incomplete recovery, direct pudendal
nerve injury or shortening of urethra below critical
functional length.11 Regarding the different etiologies of
male SUI, presumably, this can have an influence on the
outcome of surgical treatment.
TABLE 3 The outcome on the three‐item questionnaire
presented as number (%) or median (IQR)
Results of prospective follow‐up
Postoperative follow‐up in months 28.1 (12.8− 62.9)
Recommend balloons to someone else?
Yes 23 (100)
No –
PGI‐I scale
Very much better 10 (43.5)
Much better 10 (43.5)
A little better 2 (8.7)
No change 1 (4.3)
A little worse –
Much worse –
Very much worse –
Daily pad use
Preoperative 3.0 (2.0‐5.0)
Postoperative 1.0 (0.0‐2.0)
Postoperative outcome on continence
Dry 6 (26.1)
50%‐99% reduction in daily pad use 9 (39.1)
Little or no improvement 8 (34.8)
FIGURE 1 Failure‐free survival after implantation of balloons
distributed in a Kaplan‐Meier curve
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A recent systematic review addressed functional
outcome and complications in the treatment of male
postsurgical SUI with adjustable continence balloons.12
Eleven studies were included, of which six studies
included as well patients with post‐TURP SUI in the
study population. In one of the excluded studies (because
of a patient population of <20) post‐TURP SUI patients
were included as well. An overview of those seven studies
with post‐TURP SUI patients is given in Table 4.6-8,13-16
Nevertheless, none of these studies differentiated out-
come after radical prostatectomy and post‐TURP. Re-
ported dry rates varied between 4.5% and 67% and
reintervention rates varied between 14% and 46%
(Table 4). The dry rate (45%) at last outpatient visit and
reintervention rate (24%) found in the present study fall
within the respective ranges. Additionally, the previously
published results of adjustable continence balloons in
patients with SUI postradical prostatectomy implanted by
one of the surgeons of this study9 were added to Table 4
to compare with the present study. Overall, results in the
literature are slightly similar but important to note,
besides the etiology, the size, and duration of follow‐up of
study populations differ. In short, studies are hard to
compare because the etiology of SUI, history of adjuvant
radiotherapy, duration of follow‐up, different centers and
surgeons, and definitions of outcome used in the
literature are heterogeneous. Our study is hitherto the
first reporting results of adjustable continence balloons in
the treatment of post‐TURP SUI.
The median postoperative daily pad use remains
stable during follow‐up (see Tables 2 and 3). Remarkably,
we observed a decline of the dry rate at the time the PGI‐I
scale was answered. The efficacy of the balloons could
have been reduced. Another possible explanation for this
decline in dry rate could be that continent patients will
become much more active in time compared than they
were preoperative which can result in more “stress” and
a decline in dryness. Furthermore, not all patients
responded or could response and, therefore, the decline
could also partly be explained by selection bias. Despite
the decline of dry rate, the majority experienced
improvement on PGI‐I.
If conservative treatment fails, the standard in the
surgical management of male SUI is AUS.4,17,18 However,
alternatives to AUS, such as male sling and adjustable
continence devices, are available. These devices do not
require manual manipulation to void. Implantation of
adjustable continence balloons is less invasive and has
the advantages of adjusting the volume or removing the
balloons in the outpatient setting. Besides, opting for
more invasive procedures is still possible after removal.
The working mechanism of adjustable continence
balloons with a successful outcome is contributed by an
increase in urethral resistance and increased maximum
urethral closure pressure.19,20
The ICI reviewed the literature with results of AUS in
the treatment of male SUI. Most of the studies included
men with post‐prostatectomy incontinence related to
benign and malignant disease. Success rates range from
59% to 90%, defined by no or 1 pad/day, with a follow‐up
ranging from 1 to 7.7 years.3,21 To our knowledge, studies
with results of AUS in exclusively post‐TURP SUI
patients are missing.
Regarding the male sling in the treatment of post‐
TURP SUI, a few studies are published. Recently a
systematic review was published which identified 23
post‐TURP patients described in six studies who had
undergone a male sling. A successful outcome was
described in 78% of the patients with divergent defini-
tions of success (total continence, <2 g loss of urine,
≥50% pad reduction, and subjective improvement in
continence).22 Another study (not included in the above
review), reported results of 15 post‐TURP patients treated
with a male sling with a median follow‐up of
70 months.23 The outcome on continence after implanta-
tion of the male sling was improved with a greater than
or equal to 50% pad reduction in 60% of the patients,
including, 47% dry patients.23
It would be interesting to perform trials, preferably
randomized, comparing adjustable continence balloons
in the treatment of male SUI with other devices, such as a
male sling or AUS. To prevent mixed patient populations,
future studies should differentiate between patients who
have post‐radical prostatectomy SUI and those who have
post‐TURP SUI. Besides, future research to define
outcome predictors of adjustable continence balloons
could be helpful in clinical practice.
Strengths of our study are the multicenter design and
the specific study population. The etiology of the SUI was
in all patients post‐TURP SUI. These patients are a
different population with a different mechanism of injury
compared with patients with postradical prostatectomy
SUI. Both tertiary centers have around one decade of
experience in this type of surgery (10‐15 procedures/year
in Rome and 25 procedures/year in Rotterdam). Still, the
study population was relatively small which hindered
defining outcome predictors. Another limitation is
inherent to the retrospective design of our study. For
example, due to the retrospective design, we used the
IPSS in the evaluation of the adjustable continence
balloons. The IPSS is widely used in our clinical practice
and this data was available. This measure focuses on
lower urinary tract symptoms, the IPSS total score and
IPSS quality fo life (QoL) item improved significantly
after implantation. For this patient population, a condi-
tion‐specific questionnaire would be more interesting,
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such as the Urogenital Distress Inventory (UDI‐6),24 or
the Incontinence Impact Questionnaire (IIQ‐7),24 or the
International Consultation on Incontinence Question-
naire (ICIQ).25 However, the use of these questionnaires
is not widely spread and the minimal critical values have
not been established.
5 | CONCLUSION
Currently little is known about the efficacy of adjustable
continence balloons in the treatment of post‐TURP SUI.
Adjustable continence balloons seem to be safe and
efficient in the treatment of post‐TURP SUI. The majority
of our study population experienced improvement on
their condition and needed fewer pads than before the
implantation of adjustable continence balloons. Future
research is needed to compare different devices and
determine outcome predictors.
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